Sarah Ketterer's SNY Position Overview
Sarah Ketterer (via Causeway Capital Management LLC) currently holds 1.06 M shares of Sanofi (SNY) worth $51.56 M, representing 0.71% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 43 quarters.
Based on 13F filings since 2013, Sarah Ketterer has maintained a long-term strategic position in SNY, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2013, adding 317,199 shares. Largest reduction occurred in Q2 2017, reducing 208,584 shares.
Analysis based on 13F filings available since 2013 Q2
Sarah Ketterer's Sanofi (SNY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Sanofi (SNY) Trades by Sarah Ketterer
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +84,641 | Add 8.64% | 1.06 M | $48.46 |
| Q3 2025 | +139,678 | Add 16.64% | 979,317 | $47.20 |
| Q2 2025 | +146,378 | Add 21.11% | 839,639 | $48.31 |
| Q1 2025 | +2,825 | Add 0.41% | 693,261 | $55.46 |
| Q4 2024 | +192,954 | Add 38.79% | 690,436 | $48.23 |
| Q3 2024 | +16,017 | Add 3.33% | 497,482 | $57.63 |
| Q2 2024 | +15,586 | Add 3.35% | 481,465 | $48.52 |
| Q1 2024 | +23,610 | Add 5.34% | 465,879 | $48.60 |
| Q4 2023 | -38,373 | Reduce 7.98% | 442,269 | $49.73 |
| Q3 2023 | +108,574 | Add 29.18% | 480,642 | $53.64 |
| Q2 2023 | +29,650 | Add 8.66% | 372,068 | $53.90 |
| Q1 2023 | -62,039 | Reduce 15.34% | 342,418 | $54.42 |
| Q4 2022 | -59,610 | Reduce 12.85% | 404,457 | $48.43 |
| Q3 2022 | -32,614 | Reduce 6.57% | 464,067 | $38.02 |
| Q2 2022 | -113,502 | Reduce 18.60% | 496,681 | $50.03 |
| Q1 2022 | -29,122 | Reduce 4.56% | 610,183 | $51.34 |
| Q4 2021 | +3,289 | Add 0.52% | 639,305 | $50.10 |
| Q3 2021 | -50,781 | Reduce 7.39% | 636,016 | $48.21 |
| Q2 2021 | +51,841 | Add 8.16% | 686,797 | $52.66 |
| Q1 2021 | +185,370 | Add 41.23% | 634,956 | $49.46 |
| Q4 2020 | +124,878 | Add 38.46% | 449,586 | $48.59 |
| Q3 2020 | +150,423 | Add 86.31% | 324,708 | $50.17 |
| Q2 2020 | +174,285 | New Buy | 174,285 | $51.05 |
| Q1 2018 | -361 | Sold Out | 0 | $0.00 |
| Q4 2017 | -214 | Reduce 37.22% | 361 | $44.32 |
| Q3 2017 | -96,461 | Reduce 99.41% | 575 | $50.43 |
| Q2 2017 | -208,584 | Reduce 68.25% | 97,036 | $47.91 |
| Q1 2017 | -47,221 | Reduce 13.38% | 305,620 | $45.25 |
| Q4 2016 | -41,666 | Reduce 10.56% | 352,841 | $39.36 |
| Q3 2016 | +726 | Add 0.18% | 394,507 | $38.19 |
| Q2 2016 | +2,168 | Add 0.55% | 393,781 | $41.85 |
| Q1 2016 | -37,310 | Reduce 8.70% | 391,613 | $41.10 |
| Q4 2015 | -145,860 | Reduce 25.38% | 428,923 | $42.65 |
| Q3 2015 | +58,668 | Add 11.37% | 574,783 | $47.47 |
| Q2 2015 | +38,748 | Add 8.12% | 516,115 | $49.53 |
| Q1 2015 | -29,429 | Reduce 5.81% | 477,367 | $49.44 |
| Q4 2014 | -87,133 | Reduce 14.67% | 506,796 | $45.61 |
| Q3 2014 | +26,008 | Add 4.58% | 593,929 | $56.43 |
| Q2 2014 | +61,020 | Add 12.04% | 567,921 | $52.27 |
| Q1 2014 | +75,584 | Add 17.52% | 506,901 | $52.28 |
| Q4 2013 | +317,199 | Add 277.96% | 431,317 | $53.63 |
| Q3 2013 | +25,724 | Add 29.10% | 114,118 | $50.63 |
| Q2 2013 | +88,395 | Add 0.00% | 88,394 | $51.51 |
Sarah Ketterer's Sanofi Investment FAQs
Sarah Ketterer first purchased Sanofi (SNY) in Q2 2013, acquiring 88,394 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Sarah Ketterer has held Sanofi (SNY) for 43 quarters since Q2 2013.
Sarah Ketterer's largest addition to Sanofi (SNY) was in Q4 2013, adding 431,317 shares worth $23.13 M.
According to the latest 13F filing for Q4 2025, Sarah Ketterer's firm, Causeway Capital Management LLC, owns 1,063,958 shares of Sanofi (SNY), valued at approximately $51.56 M.
As of the Q4 2025 filing, Sanofi (SNY) represents approximately 0.71% of Sarah Ketterer's publicly disclosed stock portfolio, making it one of their key holdings.
Sarah Ketterer's peak holding in Sanofi (SNY) was 1,063,958 shares, as reported at the end of Q4 2025.